In addition to the above analyses, we also incorporated data from individuals treated with anti-CD20 antibody-mediated B-cell depletion, all of whom had PRL, to dissect pathology pertinent to PRL that remains unabrogated with this treatment modality, which is generally extremely effective in preventing new CNS inflammation in MS but ineffective in resolving PRL111 and limiting PRL-associated disability progression. Here, PRL is linked to myeloid sarcoma.